Fundraising FoxSanofi Ventures — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Formation.Fi is a decentralized finance platform built on Ethereum that enables users to participate in liquidity provision, yield farming, and asset swapping through automated strategies and smart contracts.
Crypto & Web3Fintech
Co-investorsGenblock CapitalAndreessen HorowitzLachy GroomSequoia CapitalThriveThrive Capital
Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesSaaSNew York, US
Ben Liu(CEO & Co-Founder)inLinhao Zhang(Co-Founder)inBenjamine Liu(Founder)Kit Dobyns(Founder)Mary Rozenman(Founder)
BoardAlfred Lin(Director)in
Co-investorsAndreessen HorowitzSequoia CapitalSam AltmanSection 32Thrive CapitalFelicis Ventures+11 more
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)
Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedInvusPoint72Venrock Healthcare Capital Partners
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactCatalio Capital ManagementInvusLeaps by BayerSixty Degree Capital
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsabrdn plcAlexandriaB CapitalDigitalis VenturesGlobal BioAccess FundLeaps by Bayer+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.